NOUL Co., Ltd. AI-powered malaria diagnostic solution miLab™ MAL has been officially adopted by Benin's National Malaria Control Program following a public procurement tender by the Ministry of Health.

Public source

Publisher name

Public post

🦟We are proud to see miLab™ MAL taking another step forward in strengthening malaria diagnostics in Africa. Noul’s AI-powered malaria diagnostic solution has been offic…

Log in to read the full post

Company

NOUL Co., Ltd.

Industry
Biotechnology Research
Location
Yongin-si, KR
Company size
51–200 employees

About NOUL Co., Ltd.

Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions. [Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities. [Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. 2. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.

See more

Latest activity

3 signals

Discover more

Similar public activity from other companies.

Customize signals for your business.

Know everything happening across the B2B world, and act on the company movements that matter to you.

© 2026 SeedOpsCompany intelligence.

SeedOps.